Assessment of oxidative stress in acute myeloid leukemia

"nBackground: Many chemotherapeutic regimens used in the treatment of cancer generate free radicals that may be a part of their beneficial effects. The aim of this study was to assess the oxidative status in patients undergoing chemotherapy for acute myeloid leukemia (AML)."n &...

Full description

Bibliographic Details
Main Authors: Esfahani A, Ghoreishi Z, Nikanfar A, Sanaat Z, Ghorbanihaghjo A, Rashtchizadeh N
Format: Article
Language:fas
Published: Tehran University of Medical Sciences 2011-02-01
Series:Tehran University Medical Journal
Subjects:
Online Access:http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/17518.pdf&manuscript_id=17518
id doaj-c60c1f7cea69403797dfed179820b333
record_format Article
spelling doaj-c60c1f7cea69403797dfed179820b3332020-11-24T20:48:04ZfasTehran University of Medical SciencesTehran University Medical Journal1683-17641735-73222011-02-016811649655Assessment of oxidative stress in acute myeloid leukemiaEsfahani AGhoreishi ZNikanfar ASanaat ZGhorbanihaghjo ARashtchizadeh N"nBackground: Many chemotherapeutic regimens used in the treatment of cancer generate free radicals that may be a part of their beneficial effects. The aim of this study was to assess the oxidative status in patients undergoing chemotherapy for acute myeloid leukemia (AML)."n "nMethods: Thirty-eight patients with AML (17 female and 21 male patients) with a mean age 34.05±12.49 years were included in the study. All the patients received cytarabine and daunorubicin as their standard induction therapy. Serum levels of malondialdehyde (MDA), total antioxidant capacity (TAC), and also the erythrocyte superoxide dismutase and glutathione peroxidase activities were measured before and 14 days after chemotherapy."n "nResults: Plasma malondialdehyde concentrations increased significantly (from a former 2.68±0.89 nmol/ml to 3.14±1.29 nmol/ml) 14 days post chemotherapy (p=0.04). Moreover, the total plasma antioxidant capacity changed from 1.09±0.15 mmol/L to 1.02±0.14 mmol/L (p=0.005). Erythrocyte superoxide dismutase and glutathione peroxidase activity decreased over time from 1157.24±543.61 U/gHb to 984.01±419.09 U/gHb (p=0.04) and 46.96±13.70 U/gHb to 41.40±6.44 U/gHb (p=0.02), respectively."n "nConclusion: In this study, an increase in malondialdehyde levels and a decrease in the levels of antioxidant enzymes and total antioxidant capacity were observed. It seems that chemotherapy by cytarabine and daunorubicin generates enormous amounts of free radicals in patients undergoing the treatment for AML. Use of antioxidant supplementation during chemotherapy i is discouraged as it may interfere with the generation of free radicals that may be a part of the therapeutic efficacy of these drugs.http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/17518.pdf&manuscript_id=17518Acute myeloid leukemiaantioxidantcytarabinedaunorubicinoxidative stress
collection DOAJ
language fas
format Article
sources DOAJ
author Esfahani A
Ghoreishi Z
Nikanfar A
Sanaat Z
Ghorbanihaghjo A
Rashtchizadeh N
spellingShingle Esfahani A
Ghoreishi Z
Nikanfar A
Sanaat Z
Ghorbanihaghjo A
Rashtchizadeh N
Assessment of oxidative stress in acute myeloid leukemia
Tehran University Medical Journal
Acute myeloid leukemia
antioxidant
cytarabine
daunorubicin
oxidative stress
author_facet Esfahani A
Ghoreishi Z
Nikanfar A
Sanaat Z
Ghorbanihaghjo A
Rashtchizadeh N
author_sort Esfahani A
title Assessment of oxidative stress in acute myeloid leukemia
title_short Assessment of oxidative stress in acute myeloid leukemia
title_full Assessment of oxidative stress in acute myeloid leukemia
title_fullStr Assessment of oxidative stress in acute myeloid leukemia
title_full_unstemmed Assessment of oxidative stress in acute myeloid leukemia
title_sort assessment of oxidative stress in acute myeloid leukemia
publisher Tehran University of Medical Sciences
series Tehran University Medical Journal
issn 1683-1764
1735-7322
publishDate 2011-02-01
description "nBackground: Many chemotherapeutic regimens used in the treatment of cancer generate free radicals that may be a part of their beneficial effects. The aim of this study was to assess the oxidative status in patients undergoing chemotherapy for acute myeloid leukemia (AML)."n "nMethods: Thirty-eight patients with AML (17 female and 21 male patients) with a mean age 34.05±12.49 years were included in the study. All the patients received cytarabine and daunorubicin as their standard induction therapy. Serum levels of malondialdehyde (MDA), total antioxidant capacity (TAC), and also the erythrocyte superoxide dismutase and glutathione peroxidase activities were measured before and 14 days after chemotherapy."n "nResults: Plasma malondialdehyde concentrations increased significantly (from a former 2.68±0.89 nmol/ml to 3.14±1.29 nmol/ml) 14 days post chemotherapy (p=0.04). Moreover, the total plasma antioxidant capacity changed from 1.09±0.15 mmol/L to 1.02±0.14 mmol/L (p=0.005). Erythrocyte superoxide dismutase and glutathione peroxidase activity decreased over time from 1157.24±543.61 U/gHb to 984.01±419.09 U/gHb (p=0.04) and 46.96±13.70 U/gHb to 41.40±6.44 U/gHb (p=0.02), respectively."n "nConclusion: In this study, an increase in malondialdehyde levels and a decrease in the levels of antioxidant enzymes and total antioxidant capacity were observed. It seems that chemotherapy by cytarabine and daunorubicin generates enormous amounts of free radicals in patients undergoing the treatment for AML. Use of antioxidant supplementation during chemotherapy i is discouraged as it may interfere with the generation of free radicals that may be a part of the therapeutic efficacy of these drugs.
topic Acute myeloid leukemia
antioxidant
cytarabine
daunorubicin
oxidative stress
url http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/17518.pdf&manuscript_id=17518
work_keys_str_mv AT esfahania assessmentofoxidativestressinacutemyeloidleukemia
AT ghoreishiz assessmentofoxidativestressinacutemyeloidleukemia
AT nikanfara assessmentofoxidativestressinacutemyeloidleukemia
AT sanaatz assessmentofoxidativestressinacutemyeloidleukemia
AT ghorbanihaghjoa assessmentofoxidativestressinacutemyeloidleukemia
AT rashtchizadehn assessmentofoxidativestressinacutemyeloidleukemia
_version_ 1716808995676618752